gog-0218: frontline bevacizumab in ovarian cancer
Published 4 years ago • 467 plays • Length 6:03Download video MP4
Download video MP3
Similar videos
-
3:47
gog-0218: which patients with ovarian cancer experience highest benefit from 1l bevacizumab?
-
7:24
ovarian cancer: maintenance following frontline bevacizumab
-
7:09
biomarker-driven frontline ovarian cancer treatment
-
3:47
frontline bevacizumab strategies in ovarian cancer
-
2:19
dr. arend on fda approval of frontline bevacizumab in ovarian cancer
-
4:43
understanding gog-0218 & icon7 trials
-
4:04
gog-0218 and icon7 trial regimens as maintenance therapy
-
8:15
bevacizumab in ovarian cancer
-
3:42
parp maintenance bevacizumab in ovarian cancer
-
26:02
updates in ovarian cancer: frontline maintenance
-
4:03
upfront bevacizumab in advanced ovarian cancer
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
4:25
adjuvant chemotherapy bevacizumab for ovarian cancer
-
7:44
frontline treatments in ovarian cancer
-
4:54
bevacizumab in recurrent ovarian cancer
-
7:57
duration of frontline therapy in ovarian cancer
-
0:47
bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
23:15
is it time to change upfront chemotherapy for ovarian cancer?